Emir

Gaming, biotech and biometrics. Biometrich is my passion. Biometric are the future . Especially Fingerprints. Nvidia,Embracer, EVO , FPC, Cantargia, Bitcoin .

[Emir @Emir05486949]

@au_azra Dan je više nego odličan.

[Emir @Emir05486949]

@10_ch_10 I read it now and it is a very good report.

[Emir @Emir05486949]

@FrillePelle I'm sure Canta will pick a new contract, pretty soon

[Emir @Emir05486949]

@au_azra Cadiz ?

[Emir @Emir05486949]

@tanjagoldie Obišao sam puno država na svim kontinentima. Zadnje četiri sedmice putujem kroz Maroko mogu reći mnoge stvari u životu sam prvi put vidio upravo u Maroku.

[FrillePelle @FrillePelle]

DXP-006, a potent "One-Drug, Multi-Pathway” antagonist of the IL1 superfamily for Dermatologic Diseases

DXP-006 is a humanized monoclonal antibody that targets the shared co-receptor IL1RAP

Fler bolag ger sig in i IL1RAP leken, validerar bara Cantargia's case!

$CANTA

[𝗧𝗶𝗺𝗲𝗹𝗲𝘀𝘀 𝗠𝘂𝘀𝗶𝗰 ✨🎵 @Hoang_HQ]

Miley Cyrus brings soulful country vibes to 'Jolene' with her emotive vocals in the Backyard Sessions, a raw and captivating performance!✨���
#countrymusic #Classichits

[Crwe World @CrweWorld]

Cantargia Closes the Acquisition of CAN10 by Otsuka #CantargiaAB, #Cantargia, #CANTA https://t.co/HUkOWMLdNQ

[Earthroamer 🌍 @Earthroamer75]

Cantargia’s New CEO Dr. Hilde Steineger Poised to Drive Growth Post-Otsuka Deal

Cantargia AB (STO:CANTA) has appointed Dr. Hilde Steineger as CEO, effective September 1, 2025, following its landmark Otsuka Pharmaceuticals deal for the CAN10 program. Here’s why her leadership could shape a promising future for Cantargia:

Proven Expertise:
With a PhD in medical biochemistry, Steineger co-founded NorthSea Therapeutics, raising $155M, and led Staten Biotechnology to a $480M Novo Nordisk deal. Her skills in finance, venture capital, and global partnerships are a strong fit for Cantargia’s ambitions.

Strategic Impact:
The Otsuka deal validates Cantargia’s IL1RAP-targeting antibodies, like nadunolimab (CAN04) for cancer and CAN10 for autoimmune diseases. Steineger’s deal-making prowess could accelerate clinical trials, especially in pancreatic cancer, NSCLC, and TNBC, while fostering new collaborations.

Outlook:
Steineger’s appointment signals Cantargia’s intent to capitalize on the Otsuka deal and elevate its global presence. Expect bold moves as she drives the pipeline forward.#Cantargia #Biotech #HildeSteineger #Otsuka

[Furkan Gözükara @FurkanGozukara]

Stockholm Sweden they are built different

[Michel Doepke @doepke_michel]

$CANTA #Cantargia +195% - announces the acquisition of its CAN10 IL1RAP immunology program by Otsuka Pharmaceutical. $33M upfront + up to $580M milestones + earn-out payments from global product sales. https://t.co/yoxNa6KPIe

[BioTech Visionary @BioTechVisions]

💉 Otsuka Pays $33M Upfront for Cantargia’s IL1RAP Antibodies—Deal Could Reach $613M!

Big move in autoimmune disease R&D:
Otsuka Pharmaceutical has acquired global rights to Cantargia’s CAN10, an IL1RAP-targeting antibody now in Phase 1 for hidradenitis suppurativa and systemic sclerosis. The deal includes a $33 million upfront, $580 million in milestones, plus royalties—and an extra preclinical backup antibody and co-development rights for future IL1RAP assets.

Cantargia’s stock jumped over 200% following the news—a major validation for both the technology and Sweden’s biotech innovation. This deal bolsters Otsuka’s strategy in autoimmune/inflammation, following recent collaborations like their Harbour BioMed pact and the Jnana acquisition.

#Otsuka #Cantargia #Autoimmune #IL1RAP #BiotechDeals #Immunology #AntibodyTherapeutics #PharmaM&A

[Emir @Emir05486949]

@Earthroamer75 Only buy for me last 3 years.

[Emir @Emir05486949]

@cantargia Only 140% up right now

[Cantargia @cantargia]

Nadunolimab with chemotherapy shows promising efficacy, especially in non-sq NSCLC post-PD-1 inhibitor, with a manageable safety profile
#canta #il1rap #biotech

https://t.co/72iHWPKMUq

[Emir @Emir05486949]

@Earthroamer75 Very nice PM. Waiting for Monday with excitement.